- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03665675
CTL específico de CMV de doador haploidêntico para tratar reativação ou infecção por CMV após órgão sólido e HCT
Estudo piloto de linfócitos T citotóxicos específicos (CTL) de doadores haploidênticos (CMV) para tratar reativação ou infecção por CMV após transplante de órgãos sólidos e células-tronco hematopoiéticas (HCT)
This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus [CMV] specific cytotoxic T-lymphocytes [CTLs]) or allogeneic adenovirus-specific cytotoxic T lymphocytes (donor adenovirus-specific [AdV] specific CTLs) work in treating CMV or AdV reactivation or infection in participants who have undergone stem cell transplant or solid organ transplant. White blood cells from donors may be able to kill cancer cells in patients with cytomegalovirus or adenovirus that has come back after a stem cell or solid organ transplant.
Visão geral do estudo
Status
Condições
Descrição detalhada
PRIMARY OBJECTIVE I. Assess the safety and feasibility of administering virus specific-CTLs from haploidentical donors in transplant patients both solid organ transplantation (SOT) and hematopoietic cell transplantation (HCT) with CMV/AdV infection despite standard therapy.
OUTLINE:Patients are assigned to 1 of 2 Cohorts.
COHORT A: Patients receive allogeneic cytomegalovirus-specific cytotoxic T lymphocytes intravenously (IV). Patients undergo blood, urine, saliva, cerebrospinal fluid (CSF), and bronchoalveolar fluid sample collection on the trial.
COHORT B: Patients receive allogeneic adenovirus-specific cytotoxic T Lymphocytes IV. Patients undergo blood, urine, saliva, CSF, and bronchoalveolar fluid sample collection on the trial.
After completion of study treatment, participants are followed up at 1 year.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase inicial 1
Contactos e Locais
Contato de estudo
- Nome: The Ohio State University Comprehensive Cancer Center
- Número de telefone: 800-293-5066
- E-mail: OSUCCCClinicaltrials@osumc.edu
Estude backup de contato
- Nome: Nicole Szuminski
- Número de telefone: 614-688-9796
- E-mail: Nicole.Szuminski@osumc.edu
Locais de estudo
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43205
- Recrutamento
- Nationwide Children's Hospital
-
Contato:
- Chris Ouellette, MD
-
Contato:
- Melinda Triplet, RN, BSN
- Número de telefone: 614-722-6039
- E-mail: Melinda.Triplet@nationwidechildrens.org
-
Columbus, Ohio, Estados Unidos, 43210
- Suspenso
- Ohio State University Comprehensive Cancer Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Patients must have solid organ transplant or have received allogeneic hematopoietic stem cell transplant.
-
• Cohort A (CMV): Must have documented CMV disease or reactivation, as by:
-
Viremia as detected by quantitative polymerase chain reaction (PCR) (> 500 IU/ml) in the peripheral blood requiring treatment OR
-
High risk for antiviral failure due to history of recurrent CMV reactivations or evidence of antiviral drug resistance, OR
-
Unable to tolerate antiviral drugs due to renal toxicity, bone marrow suppression, transfusion dependent anemia and thrombocytopenia or neutropenia requiring growth factor support or other related organ injury
• Cohort B (AdV): Must have documented AdV infection or reactivation, as by:
-
Symptomatic subject with any detectable viral load in blood, OR
-
Symptomatic subject with qualitative AdV detection in compartment of current symptomatology, including stool, urine, and/or other specimens (bronchoalveolar lavage (BAL), nasal swab, CSF, etc.), irrespective of blood viral load, OR
-
New, persistent, and/or worsening AdV-related symptoms, signs, and/or markers of end organ compromise while receiving antiviral therapy (ie cidofovir), OR
-
Asymptomatic with a viral load > 1000 copies/ml in peripheral blood, OR
-
Unable to tolerate antiviral treatment due to renal toxicity, bone marrow suppression, transfusion dependent anemia and thrombocytopenia or neutropenia requiring growth factor support or other related organ injury
- Karnofsky (age > 16 years) or Lansky performance score > 70 (age < 16)
- Available seropositive haploidentical or matched donor who is without evidence of infection that would otherwise preclude donation
- Negative pregnancy test in female patients if applicable (childbearing potential, has not received a full-intensity conditioning regimen
- Written informed consent and/or signed assent line from patient, parent or guardian
- DONOR
- Human leukocyte antigen (HLA)-haploidentical or full-match to the patient as determined by institutional standards
- Cohort A: CMV seropositive, defined as detection of serum CMV immunoglobulin G (IgG)
- Cohort B: AdV seropositive, defined as detection of serum AdV IgG
- Age 18 or over
- Meet donor eligibility or suitability according to institutional standards. If the donor is deemed ineligible according to Foundation for the Accreditation of Cellular Therapy (FACT) standards, but is suitable for donation per institutional standards, the donor will be eligible for the protocol
-
Exclusion Criteria:
-
Receipt of anti-thymocyte globulin (ATG), alemtuzumab, or other T-cell depleting agents within 21 days of screening for enrollment.
-
Receipt of > 0.5mg/kg/day of prednisone or steroid equivalent at the time of enrollment. Stable GVHD is permitted as long as patients are on stable dose steroids of less than or equal to 0.5 mg/kg/day of prednisone or steroid equivalent.
-
Evidence of uncontrolled infection as follows:
- Bacterial infections - patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment.
- Fungal infections - patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment.
- Patients with hemodynamic instability attributable to bacterial sepsis or new symptoms, worsening physical signs or radiographic findings attributable to concomitant bacterial or fungal infection are excluded. Patients who require ventilator support for CMV pneumonitis are not excluded. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
-
Receipt of donor lymphocyte infusion (DLI) within 28 days.
-
Patients with active acute graft versus host disease (GvHD) grades II-IV requiring > 0.5 mg/kg/day of prednisone or steroid equivalent or T-cell depleting immunosuppression.
-
Acute graft rejection in solid organ transplantation requiring augmented immunosuppression with T-cell depleting agents or steroids as mentioned above.
-
Active and uncontrolled relapse of malignancy.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Treatment (CMV-specific CTLs)
Participants receive allogeneic cytomegalovirus-specific cytotoxic T lymphocytes IV. Participants with persistent infection are eligible for second infusion after 28 days. |
Given intravenously |
|
Experimental: Treatment (AdV-specific CTLs)
Patients receive allogeneic adenovirus-specific cytotoxic T Lymphocytes IV. Participants with persistent infection are eligible for second infusion after 28 days. |
Given intravenously |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Viabilidade definida como a identificação de um doador adequado dentro de 4 semanas e o cumprimento das doses mínimas de células T no produto final
Prazo: Até 1 ano
|
Até 1 ano
|
|
|
Incidence of adverse events defined by the National Cancer Institute Common Terminology Criteria for Adverse Events 4.0
Prazo: Up to 30 days post infusion
|
Measured as the proportion of patients with acute (a) graft versus host disease (GvHD) grades III-IV or graft rejection/failure within 30 days of the last dose of cytotoxic T-lymphocytes (CTLs) or grades 3-5 infusion-related adverse events within 7 days of the last does of CTLs or grades 4-5 non-hematological adverse events within 30 days of the last dose of CTLs and that are not due to the pre-existing infection or the original malignancy or pre-existing co-morbidities. Will be calculated by dividing by all evaluable patients and the corresponding 95% confidence intervals will be calculated. |
Up to 30 days post infusion
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Persistência de CTLs infundidos conforme medido por rearranjo de genes de células T e efeitos sobre sinais clínicos de infecção viral
Prazo: Até 1 ano
|
Até 1 ano
|
|
|
Efeitos de CTL específicos para citomegalovírus (CMV) nas cargas virais avaliadas por reação em cadeia da polimerase com transcriptase reversa semanal
Prazo: Até 1 ano
|
Até 1 ano
|
|
|
Resposta clínica a infusões de CTL
Prazo: Com 6 semanas e 3 meses
|
Com 6 semanas e 3 meses
|
|
|
Número de participantes com eventos adversos relacionados ao tratamento, conforme avaliado pelo CTCAE v4.0".
Prazo: Até 1 ano
|
Até 1 ano
|
|
|
Antiviral activity defined as response to viral load
Prazo: At day 28
|
Complete response, partial response, stable disease or progression will be defined and proportion of each outcome will be calculated. |
At day 28
|
|
Overall survival
Prazo: From last CTL infusion till death, assessed at 6 and 12 months
|
Kaplan-Meier survival function will be used to estimate the survival probability. |
From last CTL infusion till death, assessed at 6 and 12 months
|
|
Risk for chronic GVHD
Prazo: At 6 and 12 months post CTL infusion
|
Survival analysis method will be applied. Time to chronic GVHD will be defined from time of the last CTL infusion to the onset of chronic GVHD, or the last clinical assessment date if no chronic GVHD. Cumulative incidence of chronic GVHD at 6 and 12 months will be estimated. |
At 6 and 12 months post CTL infusion
|
|
Systemic infections
Prazo: Within 6 months of CTL infusion
|
Will be reported by etiologic agent, site of disease, date of onset, and severity. |
Within 6 months of CTL infusion
|
|
Secondary graft failure
Prazo: 30 days post-CTL infusion
|
Proportion of secondary graft failure for both populations will be assessed at 30 days post CTL infusion will be calculated and 95% confidence intervals will be estimated accordingly. |
30 days post-CTL infusion
|
|
Viral reactivations
Prazo: Up to 6 months
|
Proportion of viral reactivations within 6 months will be calculated and 95% confidence intervals will be estimated accordingly. |
Up to 6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Sumithira Vasu, MBBS, Ohio State University Comprehensive Cancer Center
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- OSU-17199
- NCI-2018-01412 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .